Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Clinical Microbiology & Infectious Diseases
Published in: European Journal of Clinical Microbiology & Infectious Diseases 7/2020

01-07-2020 | Coronavirus | Review

Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening

Authors: Xiaoxuan Zhao, Yuepeng Jiang, Yang Zhao, Hongyan Xi, Chang Liu, Fan Qu, Xiaoling Feng

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 7/2020

Login to get access

Abstract

To analyze the susceptibility of SARS-CoV-2 in pregnancy and the drugs that can be used to treat pregnancy with COVID-19, so as to provide evidence for drug selection in clinic. By reviewing the existing literature, this paper analyzes the susceptibility of pregnant women to virus, especially to SARS-CoV-2, from the aspects of anatomical, reproductive endocrine and immune changes during pregnancy and screens effective and fetal-safe treatments from the existing drugs. The anatomical structure of the respiratory system is changed during pregnancy, and the virus transmitted by droplets and aerosols is more easily inhaled by pregnant women and is difficult to remove. Furthermore, the prognosis is worse after infection when compared with non-pregnancy women. And changes in reproductive hormones and immune systems during pregnancy collectively make them more susceptible to certain infections. More importantly, angiotensin-converting enzyme (ACE)-2, the SARS-CoV-2 receptor, has been proven highly increased during pregnancy, which may contribute to the susceptibility to SARS-CoV-2. When it comes to treatment, specific drugs for COVID-19 have not been found at present, and taking old drugs for new use in treating COVID-19 has become an emergency method for the pandemic. Particularly, drugs that show superior maternal and fetal safety are worthy of consideration for pregnant women with COVID-19, such as chloroquine, metformin, statins, lobinavir/ritonavir, glycyrrhizic acid, and nanoparticle-mediated drug delivery (NMDD), etc. Pregnant women are susceptible to COVID-19, and special attention should be paid to the selection of drugs that are both effective for maternal diseases and friendly to the fetus. However, there are still many deficiencies in the study of drug safety during pregnancy, and broad-spectrum, effective and fetal-safe drugs for pregnant women need to be developed so as to cope with more infectious diseases in the future.
Literature
1.
Organization. WH (2005) Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV)
2.
Kwon JY, Romero R, Mor G (2014) New insights into the relationship between viral infection and pregnancy complications. Am J Reprod Immunol 71(5):387–390PubMedPubMedCentral
3.
Price ME, Fisher-Hoch SP, Craven RB, McCormick JB (1988) A prospective study of maternal and fetal outcome in acute Lassa fever infection during pregnancy. BMJ 297(6648):584–587PubMedPubMedCentral
4.
Jamieson DJ, Uyeki TM, Callaghan WM, Meaney-Delman D, Rasmussen SA (2014) What obstetrician-gynecologists should know about Ebola: a perspective from the Centers for Disease Control and Prevention. Obstet Gynecol 124(5):1005–1010PubMed
5.
Fisk NM, Atun R (2009) Systematic analysis of research underfunding in maternal and perinatal health. BJOG 116(3):347–356PubMed
6.
Hui DS (2017) Epidemic and emerging coronaviruses (severe acute respiratory syndrome and Middle East respiratory syndrome). Clin Chest Med 38(1):71–86PubMed
7.
Song Z, Xu Y, Bao L, Zhang L, Yu P, Qu Y, Zhu H, Zhao W, Han Y, Qin C (2019) From SARS to MERS, thrusting coronaviruses into the spotlight. Viruses 11(1)
8.
Cui J, Li F, Shi ZL (2019) Origin and evolution of pathogenic coronaviruses. NAT REV MICROBIOL 17(3):181–192PubMed
9.
Brian DA, Baric RS (2005) Coronavirus genome structure and replication. Curr Top Microbiol Immunol 287:1–30PubMed
10.
Zhou Y, Jiang S, Du L (2018) Prospects for a MERS-CoV spike vaccine. Expert Rev Vaccines 17(8):677–686
11.
Su S, Wong G, Shi W, Liu J, Lai A, Zhou J, Liu W, Bi Y, Gao GF (2016) Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol 24(6):490–502PubMedPubMedCentral
12.
Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, Bi Y, Ma X, Zhan F, Wang L, Hu T, Zhou H, Hu Z, Zhou W, Zhao L, Chen J, Meng Y, Wang J, Lin Y, Yuan J, Xie Z, Ma J, Liu WJ, Wang D, Xu W, Holmes EC, Gao GF, Wu G, Chen W, Shi W, Tan W (2020) Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. LANCET 395(10224):565–574PubMedPubMedCentral
13.
Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS, McLellan JS (2020) Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367(6483):1260–1263
14.
Yan R, Zhang Y, Guo Y, Xia L, Zhou Q (2020) Structural basis for the recognition of the 2019-nCoV by human ACE2. bioRxiv:2020–2022
15.
Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, Zhang Q, Shi X, Wang Q, Zhang L, Wang X (2020) Crystal structure of the 2019-nCoV spike receptor-binding domain bound with the ACE2 receptor. bioRxiv:2020–2022
16.
EICKHOFF TC, SHERMAN IL, SERFLING RE (1961) Observations on excess mortality associated with epidemic influenza. JAMA 176:776–782PubMed
17.
Creanga AA, Johnson TF, Graitcer SB, Hartman LK, Al-Samarrai T, Schwarz AG, Chu SY, Sackoff JE, Jamieson DJ, Fine AD, Shapiro-Mendoza CK, Jones LE, Uyeki TM, Balter S, Bish CL, Finelli L, Honein MA (2010) Severity of 2009 pandemic influenza A (H1N1) virus infection in pregnant women. Obstet Gynecol 115(4):717–726PubMed
18.
Marx GF, Murthy PK, Orkin LR (1970) Static compliance before and after vaginal delivery. Br J Anaesth 42(12):1100–1104PubMed
19.
Bayliss DA, Millhorn DE (1992,) Central neural mechanisms of progesterone action: application to the respiratory system. J Appl Physiol 73(2):393–404PubMed
20.
Field SK, Bell SG, Cenaiko DF, Whitelaw WA (1991) Relationship between inspiratory effort and breathlessness in pregnancy. J Appl Physiol (1985) 71 (5):1897–1902
21.
Toppozada H, Michaels L, Toppozada M, El-Ghazzawi I, Talaat M, Elwany S (1982) The human respiratory nasal mucosa in pregnancy. An electron microscopic and histochemical study. J Laryngol Otol 96(7):613–626PubMed
22.
Bende M, Gredmark T (1999) Nasal stuffiness during pregnancy. LARYNGOSCOPE 109(7 Pt 1):1108–1110PubMed
23.
24.
25.
Nelson DM, Main E, Crafford W, Ahumada GG (1983) Peripartum heart failure due to primary pulmonary hypertension. OBSTET GYNECOL 62(3 Suppl):58s–63sPubMed
26.
27.
Silasi M, Cardenas I, Kwon JY, Racicot K, Aldo P, Mor G (2015) Viral infections during pregnancy. Am J Reprod Immunol 73(3):199–213PubMedPubMedCentral
28.
Sykes L, MacIntyre DA, Yap XJ, Ponnampalam S, Teoh TG, Bennett PR (2012) Changes in the Th1:Th2 cytokine bias in pregnancy and the effects of the anti-inflammatory cyclopentenone prostaglandin 15-deoxy-Delta(12,14)-prostaglandin J2. Mediat Inflamm 2012:416739
29.
Druckmann R, Druckmann MA (2005) Progesterone and the immunology of pregnancy. J Steroid Biochem Mol Biol 97(5):389–396PubMed
30.
Muallem G, Wagage S, Sun Y, DeLong JH, Valenzuela A, Christian DA, Harms PG, Fang Q, Buza EL, Jain D, Elloso MM, Lopez CB, Hunter CA (2017) IL-27 limits type 2 immunopathology following parainfluenza virus infection. PLoS Pathog 13(1):e1006173PubMedPubMedCentral
31.
Danza A, Ruiz-Irastorza G, Khamashta M (2016) Pregnancy in systemic autoimmune diseases: myths, certainties and doubts. Med Clin (Barc) 147(7):306–312
32.
Pazos M, Sperling RS, Moran TM, Kraus TA (2012) The influence of pregnancy on systemic immunity. Immunol Res 54(1–3):254–261PubMedPubMedCentral
33.
Zoller AL, Schnell FJ, Kersh GJ (2007) Murine pregnancy leads to reduced proliferation of maternal thymocytes and decreased thymic emigration. IMMUNOLOGY 121(2):207–215PubMedPubMedCentral
34.
Kraus TA, Engel SM, Sperling RS, Kellerman L, Lo Y, Wallenstein S, Escribese MM, Garrido JL, Singh T, Loubeau M, Moran TM (2012) Characterizing the pregnancy immune phenotype: results of the viral immunity and pregnancy (VIP) study. J Clin Immunol 32(2):300–311PubMed
35.
Klein SL, Passaretti C, Anker M, Olukoya P, Pekosz A (2010) The impact of sex, gender and pregnancy on 2009 H1N1 disease. Biol Sex Differ 1(1):5PubMedPubMedCentral
36.
Siston AM, Rasmussen SA, Honein MA, Fry AM, Seib K, Callaghan WM, Louie J, Doyle TJ, Crockett M, Lynfield R, Moore Z, Wiedeman C, Anand M, Tabony L, Nielsen CF, Waller K, Page S, Thompson JM, Avery C, Springs CB, Jones T, Williams JL, Newsome K, Finelli L, Jamieson DJ (2010) Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States. JAMA 303(15):1517–1525PubMedPubMedCentral
37.
Pierdominici M, Maselli A, Colasanti T, Giammarioli AM, Delunardo F, Vacirca D, Sanchez M, Giovannetti A, Malorni W, Ortona E (2010) Estrogen receptor profiles in human peripheral blood lymphocytes. Immunol Lett 132(1–2):79–85PubMed
38.
Piccinni MP, Lombardelli L, Logiodice F, Kullolli O, Parronchi P, Romagnani S (2016) How pregnancy can affect autoimmune diseases progression? Clin Mol Allergy 14:11PubMedPubMedCentral
39.
Bharti B, Lee SJ, Lindsay SP, Wingard DL, Jones KL, Lemus H, Chambers CD (2015) Disease severity and pregnancy outcomes in women with rheumatoid arthritis: results from the Organization of Teratology Information Specialists Autoimmune Diseases in pregnancy project. J Rheumatol 42(8):1376–1382PubMed
40.
Turner AJ, Hooper NM (2002) The angiotensin-converting enzyme gene family: genomics and pharmacology. Trends Pharmacol Sci 23(4):177–183PubMed
41.
Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, Acton S (2000) A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 87(5):E1–E9PubMed
42.
Zisman LS, Keller RS, Weaver B, Lin Q, Speth R, Bristow MR, Canver CC (2003) Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme homologue ACE2. CIRCULATION 108(14):1707–1712PubMed
43.
Averill DB, Ishiyama Y, Chappell MC, Ferrario CM (2003) Cardiac angiotensin-(1-7) in ischemic cardiomyopathy. CIRCULATION 108(17):2141–2146PubMed
44.
Hoffmann M, Kleine-Weber H, Krüger N, Müller M, Drosten C, Pöhlmann S (2020) The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. bioRxiv:2020–2021
45.
Yilin Z, Yandong N, Faguang J (2015) Role of angiotensin-converting enzyme (ACE) and ACE2 in a rat model of smoke inhalation induced acute respiratory distress syndrome. BURNS 41(7):1468–1477PubMedPubMedCentral
46.
Brosnihan KB, Neves LA, Anton L, Joyner J, Valdes G, Merrill DC (2004) Enhanced expression of Ang-(1-7) during pregnancy. Braz J Med Biol Res 37(8):1255–1262PubMed
47.
Joyner J, Neves LA, Granger JP, Alexander BT, Merrill DC, Chappell MC, Ferrario CM, Davis WP, Brosnihan KB (2007) Temporal-spatial expression of ANG-(1-7) and angiotensin-converting enzyme 2 in the kidney of normal and hypertensive pregnant rats. Am J Physiol Regul Integr Comp Physiol 293(1):R169–R177PubMed
48.
Levy A, Yagil Y, Bursztyn M, Barkalifa R, Scharf S, Yagil C (2008) ACE2 expression and activity are enhanced during pregnancy. Am J Physiol Regul Integr Comp Physiol 295(6):R1953–R1961PubMed
49.
Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, Li J, Zhao D, Xu D, Gong Q, Liao J, Yang H, Hou W, Zhang Y (2020) Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet
50.
Davies JK, Shikes RH, Sze CI, Leslie KK, McDuffie RJ, Romero R, Gibbs RS (2000) Histologic inflammation in the maternal and fetal compartments in a rabbit model of acute intra-amniotic infection. Am J Obstet Gynecol 183(5):1088–1093PubMed
51.
Salaun B, Romero P, Lebecque S (2007) Toll-like receptors’ two-edged sword: when immunity meets apoptosis. Eur J Immunol 37(12):3311–3318PubMed
52.
Madsen-Bouterse SA, Romero R, Tarca AL, Kusanovic JP, Espinoza J, Kim CJ, Kim J, Edwin SS, Gomez R, Draghici S (2010) ORIGINAL ARTICLE: the transcriptome of the fetal inflammatory response syndrome. Am J Reprod Immunol 63(1):73–92PubMedPubMedCentral
53.
Deverman BE, Patterson PH (2009) Cytokines and CNS development. NEURON 64(1):61–78PubMed
54.
Shi L, Smith SE, Malkova N, Tse D, Su Y, Patterson PH (2009) Activation of the maternal immune system alters cerebellar development in the offspring. Brain Behav Immun 23(1):116–123PubMed
55.
Smith SE, Li J, Garbett K, Mirnics K, Patterson PH (2007) Maternal immune activation alters fetal brain development through interleukin-6. J Neurosci 27(40):10695–10702PubMedPubMedCentral
56.
Li CC, Wang XJ, Wang HR (2019) Repurposing host-based therapeutics to control coronavirus and influenza virus. Drug Discov Today 24(3):726–736PubMedPubMedCentral
57.
Roberts SS, Miller RK, Jones JK, Lindsay KL, Greene MF, Maddrey WC, Williams IT, Liu J, Spiegel RJ (2010) The ribavirin pregnancy registry: findings after 5 years of enrollment, 2003-2009. Birth Defects Res A Clin Mol Teratol 88(7):551–559PubMed
58.
de Ruiter A, Taylor GP, Clayden P, Dhar J, Gandhi K, Gilleece Y, Harding K, Hay P, Kennedy J, Low-Beer N, Lyall H, Palfreeman A, O'Shea S, Tookey P, Tosswill J, Welch S, Wilkins E (2014) British HIV Association guidelines for the management of HIV infection in pregnant women 2012 (2014 interim review). HIV MED 15(Suppl 4):1–77PubMed
59.
Colbers A, Greupink R, Burger D (2013) Pharmacological considerations on the use of antiretrovirals in pregnancy. Curr Opin Infect Dis 26(6):575–588PubMed
60.
Plantone D, Koudriavtseva T (2018) Current and future use of chloroquine and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases: a mini-review. CLIN DRUG INVEST 38(8):653–671
61.
Keyaerts E, Li S, Vijgen L, Rysman E, Verbeeck J, Van Ranst M, Maes P (2009) Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice. Antimicrob Agents Chemother 53(8):3416–3421PubMedPubMedCentral
62.
Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, Seidah NG, Nichol ST (2005) Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2:69PubMedPubMedCentral
63.
Keyaerts E, Vijgen L, Maes P, Neyts J, Van Ranst M (2004) In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun 323(1):264–268PubMedPubMedCentral
64.
Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, Choe H, Farzan M (2003) Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. NATURE 426(6965):450–454PubMedPubMedCentral
65.
Lazzaroni MG, Dall'Ara F, Fredi M, Nalli C, Reggia R, Lojacono A, Ramazzotto F, Zatti S, Andreoli L, Tincani A (2016) A comprehensive review of the clinical approach to pregnancy and systemic lupus erythematosus. J Autoimmun 74:106–117PubMed
66.
Silva JC, Mariz HA, Rocha LJ, Oliveira PS, Dantas AT, Duarte AL, Pitta IR, Galdino SL, Pitta MG (2013) Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients. Clinics (Sao Paulo) 68(6):766–771
67.
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G (2020) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30(3):269–271
68.
Klumpp TG (1965) Safety of chloroquine in pregnancy. JAMA 191 (9):765
69.
Kaplan YC, Ozsarfati J, Nickel C, Koren G (2016) Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis. Br J Clin Pharmacol 81(5):835–848PubMedPubMedCentral
70.
71.
Haagmans BL, Kuiken T, Martina BE, Fouchier RA, Rimmelzwaan GF, van Amerongen G, van Riel D, de Jong T, Itamura S, Chan KH, Tashiro M, Osterhaus AD (2004) Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat Med 10(3):290–293PubMedPubMedCentral
72.
Loutfy MR, Blatt LM, Siminovitch KA, Ward S, Wolff B, Lho H, Pham DH, Deif H, LaMere EA, Chang M, Kain KC, Farcas GA, Ferguson P, Latchford M, Levy G, Dennis JW, Lai EK, Fish EN (2003) Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA 290(24):3222–3228PubMed
73.
74.
Shalhoub S, Farahat F, Al-Jiffri A, Simhairi R, Shamma O, Siddiqi N, Mushtaq A (2015) IFN-alpha2a or IFN-beta1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study. J Antimicrob Chemother 70(7):2129–2132PubMed
75.
Yazdani BP, Matok I, Garcia BF, Koren G (2012) A systematic review of the fetal safety of interferon alpha. Reprod Toxicol 33(3):265–268
76.
van der Lee M, Sankatsing R, Schippers E, Vogel M, Fatkenheuer G, van der Ven A, Kroon F, Rockstroh J, Wyen C, Baumer A, de Groot E, Koopmans P, Stroes E, Reiss P, Burger D (2007) Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients. Antivir Ther 12(7):1127–1132PubMed
77.
Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS, Kao RY, Poon LL, Wong CL, Guan Y, Peiris JS, Yuen KY (2004) Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. THORAX 59(3):252–256PubMedPubMedCentral
78.
Lin S, Shen R, Guo X (2020) Molecular modeling evaluation of the binding abilities of ritonavir and lopinavir to Wuhan pneumonia coronavirus proteases. bioRxiv:2020–2021
79.
Koss CA, Natureeba P, Plenty A, Luwedde F, Mwesigwa J, Ades V, Charlebois ED, Clark TD, Achan J, Ruel T, Nzarubara B, Kamya MR, Havlir DV, Cohan D (2014) Risk factors for preterm birth among HIV-infected pregnant Ugandan women randomized to lopinavir/ritonavir- or efavirenz-based antiretroviral therapy. J Acquir Immune Defic Syndr 67(2):128–135PubMedPubMedCentral
80.
Roberts SS, Martinez M, Covington DL, Rode RA, Pasley MV, Woodward WC (2009) Lopinavir/ritonavir in pregnancy. J Acquir Immune Defic Syndr 51(4):456–461PubMed
81.
Kaufmann S, Dorhoi A, Hotchkiss RS, Bartenschlager R (2018) Host-directed therapies for bacterial and viral infections. Nat Rev Drug Discov 17(1):35–56PubMed
82.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. LANCET 395(10223):497–506PubMedPubMedCentral
83.
Zumla A, Hui DS, Azhar EI, Memish ZA, Maeurer M (2020) Reducing mortality from 2019-nCoV: host-directed therapies should be an option. LANCET 395(10224):e35–e36PubMedPubMedCentral
84.
Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY (2016) Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov 15(5):327–347PubMedPubMedCentral
85.
Beigel JH, Nam HH, Adams PL, Krafft A, Ince WL, El-Kamary SS, Sims AC (2019) Advances in respiratory virus therapeutics - a meeting report from the 6th isirv antiviral group conference. Antivir Res 167:45–67PubMed
86.
Zmijewski JW, Lorne E, Zhao X, Tsuruta Y, Sha Y, Liu G, Siegal GP, Abraham E (2008) Mitochondrial respiratory complex I regulates neutrophil activation and severity of lung injury. Am J Respir Crit Care Med 178(2):168–179PubMedPubMedCentral
87.
Gilbert C, Valois M, Koren G (2006) Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis. Fertil Steril 86(3):658–663PubMed
88.
Li G, Zhao S, Cui S, Li L, Xu Y, Li Y (2015) Effect comparison of metformin with insulin treatment for gestational diabetes: a meta-analysis based on RCTs. Arch Gynecol Obstet 292(1):111–120PubMed
89.
Fedson DS (2013) Treating influenza with statins and other immunomodulatory agents. Antivir Res 99(3):417–435PubMed
90.
Pollack PS, Shields KE, Burnett DM, Osborne MJ, Cunningham ML, Stepanavage ME (2005) Pregnancy outcomes after maternal exposure to simvastatin and lovastatin. Birth Defects Res A Clin Mol Teratol 73(11):888–896PubMed
91.
Zumla A, Azhar EI, Arabi Y, Alotaibi B, Rao M, McCloskey B, Petersen E, Maeurer M (2015) Host-directed therapies for improving poor treatment outcomes associated with the middle east respiratory syndrome coronavirus infections. Int J Infect Dis 40:71–74PubMedPubMedCentral
92.
Kennedy DA, Lupattelli A, Koren G, Nordeng H (2016) Safety classification of herbal medicines used in pregnancy in a multinational study. BMC Complement Altern Med 16:102PubMedPubMedCentral
93.
Asl MN, Hosseinzadeh H (2008) Review of pharmacological effects of Glycyrrhiza sp. and its bioactive compounds. Phytother Res 22(6):709–724PubMedPubMedCentral
94.
Peiris JS, Chu CM, Cheng VC, Chan KS, Hung IF, Poon LL, Law KI, Tang BS, Hon TY, Chan CS, Chan KH, Ng JS, Zheng BJ, Ng WL, Lai RW, Guan Y, Yuen KY (2003) Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. LANCET 361(9371):1767–1772PubMedPubMedCentral
95.
Goldstein JL, Silverstein FE, Agrawal NM, Hubbard RC, Kaiser J, Maurath CJ, Verburg KM, Geis GS (2000) Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 95(7):1681–1690PubMed
96.
Strandberg TE, Andersson S, Jarvenpaa AL, McKeigue PM (2002) Preterm birth and licorice consumption during pregnancy. Am J Epidemiol 156(9):803–805PubMed
97.
Raikkonen K, Pesonen AK, Heinonen K, Lahti J, Komsi N, Eriksson JG, Seckl JR, Jarvenpaa AL, Strandberg TE (2009) Maternal licorice consumption and detrimental cognitive and psychiatric outcomes in children. Am J Epidemiol 170(9):1137–1146PubMed
98.
Choi JS, Han JY, Ahn HK, Ryu HM, Kim MY, Chung JH, Nava-Ocampo AA, Koren G (2013) Fetal and neonatal outcomes in women reporting ingestion of licorice (Glycyrrhiza uralensis) during pregnancy. Planta Med 79(2):97–101PubMed
99.
Li HY, Xu W, Su J, Zhang X, Hu LW, Zhang WD (2010) In vitro and in vivo inhibitory effects of glycyrrhetinic acid on cytochrome P450 3A activity. PHARMACOLOGY 86(5–6):287–292PubMed
100.
101.
Caster JM, Patel AN, Zhang T, Wang A (2017) Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials. Wiley Interdiscip Rev Nanomed Nanobiotechnol 9(1)
102.
Flemming A (2011) Vaccines: nano-adjuvant: double TLR stimulation is the key. Nat Rev Drug Discov 10(4):258PubMed
103.
Keelan JA, Leong JW, Ho D, Iyer KS (2015) Therapeutic and safety considerations of nanoparticle-mediated drug delivery in pregnancy. Nanomedicine (Lond) 10(14):2229–2247
104.
Wick P, Malek A, Manser P, Meili D, Maeder-Althaus X, Diener L, Diener PA, Zisch A, Krug HF, von Mandach U (2010) Barrier capacity of human placenta for nanosized materials. Environ Health Perspect 118(3):432–436PubMed
105.
Menjoge AR, Rinderknecht AL, Navath RS, Faridnia M, Kim CJ, Romero R, Miller RK, Kannan RM (2011) Transfer of PAMAM dendrimers across human placenta: prospects of its use as drug carrier during pregnancy. J Control Release 150(3):326–338PubMed
106.
Menezes V, Malek A, Keelan JA (2011) Nanoparticulate drug delivery in pregnancy: placental passage and fetal exposure. Curr Pharm Biotechnol 12(5):731–742PubMed
Metadata
Title
Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening
Authors
Xiaoxuan Zhao
Yuepeng Jiang
Yang Zhao
Hongyan Xi
Chang Liu
Fan Qu
Xiaoling Feng
Publication date
01-07-2020
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 7/2020
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-020-03897-6

Other articles of this Issue 7/2020

European Journal of Clinical Microbiology & Infectious Diseases 7/2020 Go to the issue

Original Article

Clinical impact of rapid susceptibility testing on Mueller-Hinton Rapid-SIR directly from urine specimens

Original Article

Effect of Saccharomyces boulardii CNCM I-745 as complementary treatment of Helicobacter pylori infection on gut microbiome

Original Article

Group A streptococcal bacteremias in Southwest Finland 2007–2018: epidemiology and role of infectious diseases consultation in antibiotic treatment selection

Original Article

Impact of early neuraminidase inhibitor treatment on clinical outcomes in patients with influenza B-related pneumonia: a multicenter cohort study

Original Article

Emergence of vancomycin-resistant Enterococcus faecium ST1421 lacking the pstS gene in Korea

Original Article

Trends in diagnostic methods and treatment of latent tuberculosis infection in a tertiary care center from 2000 to 2017
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits